linjc16/ctgov huggingface dataset:
Endometrial Genomic Profile in Endometrial Priming

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to analyse genomics profile expression in endometrium under different endometrial priming for recipients.

Detailed Description
-----------------
We analyze the genomic profile of egg donors in different endometrial priming protocols, compared with natural cycle, including the conventional single long acting GnRH agonist injection in the mid luteal phase of the previous cycle of the endometrial priming and the single daily antagonist injection (Cetrorelix 0.25 mg) administered in the early follicular phase followed by endometrial priming. Endometrial biopsy will be taken in luteinizing hormone 7 or with P4 +5 in cases with endometrial priming with oestrogens therapy.

Official Title
-----------------
Profile Study of Genomics Endometrial Expression After Gonadotropin-releasing Hormone Agonist Administration and GnRH in Endometrial Priming.

Conditions
-----------------
Genomic Human Endometrial Expression Profile

Intervention / Treatment
-----------------
* Procedure: endometrial biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 6 egg healthy volunteer egg donors. Volunteers. 18-35 years old Healthy. BMI <28. Exclusion Criteria: - BMI > 28 Smokers-

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Natural cycle<br>Natural cycle endometrial biopsy, lh+7 | Procedure: endometrial biopsy<br>* endometrial biopsy<br>|
| Experimental: Antagonist cycle + endometrial priming.<br>Antagonist cycle + endometrial priming for egg donation program. endometrial biopsy, p4+5 | Procedure: endometrial biopsy<br>* endometrial biopsy<br>|
| Experimental: Agonist cycle + endometrial priming.<br>Agonist cycle + endometrial priming for egg donation program endometrial biopsy, p4+5 | Procedure: endometrial biopsy<br>* endometrial biopsy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| genetic endometrial human profile expression | implantation related genes profile expression | Oocyte donors will be followed up for four to six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endometrial priming, genomic expression. Natural cycle. Antagonist GnRH.
Treatment Choices for Improving Adherence and Outcome

Study Overview
=================
Brief Summary
-----------------
This study will determine the effectiveness of offering primary care patients their preferred treatment versus one that is less desirable in improving treatment adherence and outcome.

Detailed Description
-----------------
This study investigates whether offering primary care patients treatment that is congruent with their preferred first choice improves adherence and outcomes, in comparison to offering treatment that is not congruent with their preferred first choice. All subjects are offered a treatment with demonstrated efficacy, namely either the antidepressant medication escitalopram or Interpersonal Psychotherapy for 5 months. We hypothesize that patients who receive congruent treatment will be more likely to initiate treatment, adhere to treatment, and achieve depression remission.

Official Title
-----------------
Patient Preference in Primary Care Depression Treatment

Conditions
-----------------
Major Depression

Intervention / Treatment
-----------------
* Drug: escitalopram
* Behavioral: interpersonal psychotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 21-99 English-speaking DSM-IV criteria for major depression Exclusion Criteria: unable to give informed consent MMSE<24 DSM-IV diagnosis of bipolar disorder, psychotic disorder, current alcohol or substance abuse active suicide ideation aphasia acute or severe medical illness currently receiving either antidepressant medication or psychotherapy

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: escitalopram|nan|
|Behavioral: interpersonal psychotherapy|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| treatment initiation |  |  | 
| treatment adherence |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| depressive symptomatology |  |  |
Treatment of AIDS Vacuolar Myelopathy With Methionine

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.

Detailed Description
-----------------
Myelopathy is usually a late complication of AIDS, and until recently its symptoms were rarely recognized, masked by the general state of disability or the presence of other neurological complications. With prolonged survival and improved quality of life of HIV-infected patients, myelopathy is increasingly becoming a common source of disability. The cause of AIDS-myelopathy is unknown, but it is probably an indirect effect of the long-term presence of the HIV virus in the nervous system rather than the result of a direct infection. The purpose of this study is to determine whether methionine, an amino acid present in low doses in the normal diet, can improve myelopathy or stop its progression.

Conditions
-----------------
Myelopathy, AIDS-Myelopathy, AIDS Vacuolar Myelopathy

Intervention / Treatment
-----------------
* Drug: methionine


Participation Criteria
=================
Eligibility Criteria
-----------------
Between 18 and 80 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: methionine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AIDS-myelopathy, myelopathy, AIDS vacuolar myelopathy, methionine
Therapeutic Equivalence Study of HCP0910 250/50 Mcg to Seretide 250 Diskus in Asthmatic Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to prove that HCP0910 is therapeutically equivalent to Seretide 250 Diskus when repeatedly dosed to Asthmatic patients.

Official Title
-----------------
A Phase I, Randomized, Open, Multi-center, Cross Over Study to Evaluate the Therapeutic Equivalence of Repeated Dose of HCP0910 250/50 μg to SeretideTM 250 DiskusTM in Asthmatic Patients

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: HCP0910
* Drug: Seretide Diskus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 20   75 inclusive Asthmatic diagnosis in more than 12 weeks from screening day Shows more than 12 % increase, and 200mL increase in FEV1 measure on Visit 2 Exclusion Criteria: Maintain controlled asthma for more than 4 weeks before screening Diagnosed as a severe asthmatic patients

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: HCP0910<br>Fluticasone /salmeterol 250/50 combination capsule | Drug: HCP0910<br>* 250/50, BID for 2 weeks<br>|
| Active Comparator: Seretide Diskus<br>Seretide 250 Diskus | Drug: Seretide Diskus<br>* 250/50, BID for 2 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mean change of morning predose FEV1 from baseline |  | day 14 |
Diagnostic Algorithm in Patients With Minor Head Injury

Study Overview
=================
Brief Summary
-----------------
The objective of this prospective study is to evaluate the reliability of plain x-rays vs.cranial computed tomography as a screening method for skull fractures and its prognostic value for intracranial bleeding (ICB).

Detailed Description
-----------------
In a consecutive patients series of about 12500, blunt head injuries were observed (during a 16 month period), in a prospective analysis. Based on a retrospective study, we created a checklist of individual patients data which was completed for each patient. In accordance with the institutions guidelines all patients with blunt head injury received plain skull x-ray in 2 plains and additional cranial CT-scan (CCT) in case of fracture or neurological symptoms. We developed also an diagnostic algorithm consisting of anamnestical data and clinical signs and symptoms to define these risk factors and to catch all patients with minor head injury who are at risk to develop intracranial bleeding.

Official Title
-----------------
Prospective Study to Find a Diagnostic Algorithm for Diagnosis of Minor Head Injury

Conditions
-----------------
Minor Head Injury, Traumatic Brain Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: head injury, nausea, vomiting Exclusion Criteria: no head injury
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Minor head injury<br>patients with minor head injury | |
| minor head injury<br>patients with minor head injury | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
risk factors, plain x ray, cranial computed tomography, minor head injury
Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation

Study Overview
=================
Brief Summary
-----------------
This project will facilitate the optimization of body MR imaging at 3 Tesla.

Detailed Description
-----------------
This project is meant to improve the image quality of multiple sequences at 3.0T applied to the abdominal and pelvic regions.

Official Title
-----------------
Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation

Conditions
-----------------
Diffuse and Focal Abnormalities of the Liver and Pancreas

Intervention / Treatment
-----------------
* Device: Body MR imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects between ages of 19 and 65 Healthy volunteer subjects should not have any history of disease or symptoms - based on clinical history Subjects with an underlying disorder (diffuse and focal abnormalities of the liver and pancreas) Exclusion Criteria: Inability to provide informed consent A medical or contraindications that will prevent subjects from having a MRI Subjects with severe renal dysfunction or patients on dialysis

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Body MRI healthy volunteers<br>Body MRI to optimize sequences in healthy individuals and in disorder subjects | Device: Body MR imaging<br>* Body MR imaging will be performed to optimize sequences<br>* Other names: Body MR imaging performed to optimize sequences;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Optimizing body MR imaging sequences | Healthy volunteers will be used to obtain optimized body MR imaging sequences that will then be used to evaluate MR imaging sequences of subjects with underlying disorders. | 2 years |
Evaluation of a Novel and Simplified Technique for Intrauterine Contraceptive Devices Insertion: a Prospective Cohort Study

Study Overview
=================
Brief Summary
-----------------
The intrauterine devices (IUDs) are a safe, reliable, long-acting and reversible contraceptive method. It is also sound safe and cheap contraceptive methods available and is nearly maintenance free for up to 10 years. The fear and the pain associated with IUDs insertion consider barriers to using this contraception method, this is because that the mucosal lining of female genital tract is highly sensitive to touch and pain. However; most of small procedures done in this sensitive area are performed without analgesia. The pain during IUDs insertion is due to application of the tenaculum , traction of the cervical canal, passing the uterine sound, insertion of the IUDs through the cervix, and irritation of the endometrial lining by the IUDs.

Conditions
-----------------
Contraception

Intervention / Treatment
-----------------
* Other: IUD
* Other: Uterine sounding
* Radiation: Transvaginal ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women requesting intrauterine contraceptive device as a contraction Women accepted participation in the study Exclusion Criteria: Uterine abnormalities Endometrial lesions as polyp Adenomyosis Fibroids distorting the cavity Intrauterine adhesions. Chronic pelvic pain Dysmenorrhea History of cervical surgery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Group I: IUD without uterine sound group<br>Transvaginal ultrasound before to intrauterine contraceptive device insertion without uterine sounding. | Other: IUD<br> <br> Radiation: Transvaginal ultrasound<br> <br> |
| Other: Group II: IUD with uterine sound<br>Intrauterine contraceptive device inserted by classic method | Other: IUD<br> <br> Other: Uterine sounding<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The degree of pain perception measured visual analogue score |  | 15 minutes |
2D and Tissue Doppler Imaging Echocardiography Analysis of Left Ventricular Regional Wall Motion and Prognosis

Study Overview
=================
Brief Summary
-----------------
Development of myocardial ischemia, and/or myocarditis would induce different changes in myocardial contraction behavior pattern,which maybe very subtle, and may not be detected by the 2D and m-mode echocardiography examinations. According to tissue Doppler imaging(TDI), they can be depicted by different models of echo with higher frame rates. In addition, many studies using TDI have significantly contributed of efforts to evaluate systolic and diastolic function and prognosis. This study assess the value of the indices of left ventricular function obtained by using TDI in patient with coronary artery disease(CAD). We hypothesized that TDI will add incremental value for regional wall motion abnormality of CAD and its prognosis.

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Angina Acue coronary syndrome Left ventricular systolic dysfunction Exclusion Criteria: Significant valvular disease Active cancer status Acute Renal failure Contrast allergy history Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| one,two,and three vessels disease; mortality<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all cause mortality |  | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CAD
Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the efficacy, safety and tolerance of 2 different dose levels of oral NXL103 with oral comparator in the treatment of community acquired pneumonia in adults

Official Title
-----------------
A Double-Blind, Multicenter, Randomized, Double Dummy, Three-Arm Parallel-Group Comparative Study of the Efficacy, Safety and Tolerance of Oral NXL 103 Versus Oral Comparator in the Treatment of Community-Acquired Pneumonia in Adults

Conditions
-----------------
Community Acquired Pneumonia

Intervention / Treatment
-----------------
* Drug: NXL103
* Drug: comparator
* Drug: NXL103


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Community acquired pneumonia Exclusion Criteria: severe CAP respiratory infections attributed to sources other than community acquired bacterial infection concomitant pulmonary disease history of hypersensitivity to study medication, macrolide or beta lactam antibiotics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>NXL103 | Drug: NXL103<br>* 500mg orally twice daily<br>|
| Active Comparator: 3<br> | Drug: comparator<br>* comparator twice daily<br>|
| Experimental: 2<br>NXL103 | Drug: NXL103<br>* 600mg orally twice daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate Clinical outcome |  | early follow up visit (day 14 to 21) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate bacteriological outcome |  | early follow up visit (day 14 to 21) | 
| Evaluate safety |  | first dose, throughout treatment, and to follow up visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CAP, community acquired pneumonia
Prevalence Rate of Pulmonary Embolism Among Not Anticoagulated Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the prevalence rate of pulmonary embolism among not anticoagulated patient older than 75 years old admitted with syncope and hospitalised in the Toulon Hospital

Detailed Description
-----------------
This study will be proposed to every patient that correspond to eligibility criteria. Will be included only those who are not opposed to the collection of their data. The data collected will come from the routine care such as medical history, clinical datas, imaging data… The number of pulmonary imaging will be assessed before the diagnostic strategy proposed by Dr Prandoni and after the application of this strategy thanks to a questionnaire to physicians.

Official Title
-----------------
MeAsurement of uneXpected Acute Pulmonary embolIsM Among Not Anticoagulated Patients Older Than 75 Years Admitted With Syncope.

Conditions
-----------------
Pulmonary Embolism

Intervention / Treatment
-----------------
* Other: data collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female over 75 years-old Emergency consult resulting on an hospitalization in the geriatric service or in the internal medicine service Hospitalised in the Centre Hospitalier Intercommunal de Toulon for syncope, presenting these symptoms: Loss of consciousness with quick return to normal (less than one minute) Spontaneous resolution Exclusion Criteria: history of syncope other loss of consciousness (epilepsy, stroke, head trauma) anticoagulated treatment patient's objection

Ages Eligible for Study
-----------------
Minimum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pulmonary embolism<br>data from routine care will be collected for patient eligible and willing to participate | Other: data collection<br>* data from patient included will be collected during the study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pulmonary embolism prevalence | Prevalence rate of pulmonary embolism among patient hospitalized for syncope and diagnosed with ventilation/perfusion scan or CT scan. | 24 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the impact of the Prandoni's recommendations on the paraclinical evaluations | Number of CT-scans that are made systematically since the Prandoni's recommendations are applied in the hospital | 24 month |